CIK 0001953926 · <br>Emerging growth company
Zenas BioPharma, Inc.
Sign in to watch- Ticker
- ZBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857-271-2954
- Business address
- 852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
- Former names
- Zenas BioPharma (Cayman) Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +1,505,388 | 1,505,388 | ||
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Purchase | +441,176 | $17.00 | $7.5M | 1,946,564 |
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +501,796 | 501,796 | ||
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Purchase | +1,352,942 | $17.00 | $23.0M | 1,854,738 |
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion | +669,061 | 669,061 | ||
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Purchase | +441,176 | $17.00 | $7.5M | 1,110,237 |
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series C Convertible Preferred Stock | −13,071,439 | 0 | ||
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series C Convertible Preferred Stock | −4,357,146 | 0 | ||
| 2024-09-16 | SR ONE CAPITAL MANAGEMENT, LLC 10% owner | Conversion · Series C Convertible Preferred Stock | −5,809,528 | 0 | ||
| 2024-09-13 | Lu Hongbo Director | Purchase | +58,823 | $17.00 | $1000K | 58,823 |
| 2024-09-13 | Lu Hongbo Director | Purchase | +58,823 | $17.00 | $1000K | 58,823 |
| 2024-09-12 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2024-09-12 | MOULDER LEON O JR Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,486,000 | 1,486,000 | ||
| 2024-09-12 | ORLOFF JOHN J Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2024-09-12 | Xiao Ting Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2024-09-12 | Lu Hongbo Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2024-09-12 | Allen Patricia L Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2024-09-12 | ENRIGHT PATRICK G Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2024-09-12 | Boylan James P Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2024-09-12 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 |
Page 7 of 8 · 145 trades